IMO, there was no reason for today's drop, other than the overall market tanked. I also think those that had brought in the $10-$15 PPS range may have been shaken to the point to lock in their profits, rather than risk a further decrease in the PPS. We'll see how things shake out in the next quarters, since my horizon is long term.
Your comment is spot on. The question is whether we think sapphire prices will recover in the next 1.5 years. Their talk on the CC about their prototype and proof of concept for other applications with sapphire (e.g. single crystal growth, sapphire on glass, sapphire on plastic, etc) is years away. RBCN only has the next 1.5 years to begin being cash-flow positive in order to survive.
The one thing I don't understand, with all things being similar next quarter as this quarter, you would think the announced $9M contract would boost their top line. $9M over 4 qtrs is an additional $2.25M in revenue each quarter. GLTA. I may add some shares at this low level, but it's a risk.
Same here. The trading today does not seem to match the earnings report. Hopefully it's just people who brought at the $10 low and taking some profits off the table. But I think it can go higher. So I'm holding for now until at least $35. GLTA.
They beat estimates by 2 cents. Not sure why AH trading is down..
Can someone explain if the two trials and drugs are competing for the same space? And if not, how are the two different? Thanks in advance. GLTA.
I agree. It seemed like K. King was out to lunch as the stock price tanked? Maybe O.B. Parrish will bring a sense of urgency to their plans moving forward and layout a concrete plan at the next CC and not just vague statements and time frames. If not, it'll be just more of the same while the PPS goes even lower. GLTA.
$1.80 PPS. By the time management announces their acquisition plans, the PPS could be at $1 and it'll "pop" 25% to $1.25. They seem to have absolutely no urgency as we hit new lows week over week.
The big unknown is whether the other competitors have learned from the last tender and are prepared to deliver their awarded share. In which case, all FHCO will deliver is up to 11M units. The other competitors must have made a compelling case, otherwise why would South Africa award the tender to a company that they know will not be able to deliver on their contract.
Although they tried to put a good spin on just receiving only 20% of the tender, I'm a bit disappointed with the outcome. Time will tell. But what I found encouraging, was the information that they will finally launch the consumer initiative at the end of this year. This also seems to coincide with the timing of the product diversification initiative.
Maybe the two actions at the same time will provide a bump to the PPS. GLTA.
I agree. Management also does not seem to have a sense of urgency in diversifying their products and implementing their plan to get their product out to the consumers.
I agree. I think that both arms are performing better than expected. Let's just hope cabo can outrun Everolimus in the end. GLTA.